U.S. FDA issues seven observations to Dr. Reddy’s biologics manufacturing facility in Hyderabad
The U.S. Food and Drug Administration (USFDA) has issued seven observations to Dr. Reddy’s Laboratories' biologics manufacturing facility in Hyderabad following a pre-licence inspection. The company is required to address these findings within a specified timeline.
Why it matters
Regulatory scrutiny from the USFDA is a critical factor for Indian pharmaceutical companies, as it impacts their ability to export products to the U.S. market.
The U.S. Food and Drug Administration (USFDA) has issued seven observations to the biologics manufacturing facility of Dr. Reddy’s Laboratories in Bachupally, Hyderabad.
The report is a factual summary of a regulatory filing without editorializing or speculation.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in